Alex Gutteridge

Director & Head, Bioinformatics

Alex has over twelve years of pharmaceutical, CDMO, and biotech industrial experience with a focus on using omics data, ML, and AI for drug discovery, in particular through proteomics, functional genomics, and statistical genetics. Alex was awarded his PhD in Computational Biology and an MBA from the University of Cambridge which was followed by post-doctoral appointments at the Universities of Kyoto and Cambridge. Alex has managed computational biology teams and drug discovery projects at Pfizer, GSK, and Lonza including the use of iPSC models, statistical genetics, and network machine learning for drug target identification. At GSK Alex was the Scientific Lead for Open Targets, a collaboration between the European Bioinformatics Institute, Wellcome Trust Sanger Institute, and multiple pharma partners hunting for new drug targets in oncology, immunology, and CNS disorders. After co-founding Enedra Therapeutics, an early-stage biotech start-up focusing on the application of ML and AI to develop novel cancer therapies through functional genomics, Alex is now Head of Bioinformatics at Dunad Therapeutics. Dunad’s Claymor TPD-covalent platform uniquely combines cutting-edge approaches to covalently targeting disease-causing proteins with the body’s natural protein quality-control machinery to selectively delete these proteins and improve disease outcomes.

Talks About
#bioinformatics #research

Preferred Locations
#Northamerica